MannKind Corp.'s (NASDAQ: MNKD) short interest, at around 116.06 million shares as of July 31, was up about 3% from the previous period. Note that was 45.3% of the total float, and the days to cover fell from more than 25 to about 19. Peak short interest year to date was more than 131 million shares, back in May. MannKind's inhaled insulin drug Afrezza has moved out of clinical development into the commercial market. Shares ended Tuesday at $4.16, in a 52-week range of $3.46 to $8.29.